Squamous cell carcinoma of the anal canal · line 1 · Nigro protocol (mitomycin-C + 5-FU + RT, anal SCC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-NIGRO-MMC-5FU-RT |
| ID | IND-ANAL-SCC-LA-1L-NIGRO-CRT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-ANAL-SCC |
| Sources | SRC-ACT2-JAMES-2013 SRC-NCCN-ANAL-2025 |
Notes
Post-CRT surveillance: physical exam + inguinal node palpation q3-6 months × 5 years; CT CAP q6-12 months × 2 years; MRI pelvis q6 months × 2 years (sensitive for local recurrence). Recurrence after CRT: local-only → consider salvage APR if resectable; distant → systemic therapy. HIV+ patients: same CRT protocol; coordinate with HIV specialist; CD4 >200 preferred but not absolute contraindication; ART must continue during CRT.
Used By
Algorithms
ALGO-ANAL-SCC-1L- ALGO-ANAL-SCC-1L